April 26, 2018 / 8:44 PM / 3 months ago

BRIEF-Vertex Initiates Phase 3 Studies Of Vx-445, Tezacaftor And Ivacaftor

April 26 (Reuters) - Vertex Pharmaceuticals Inc:

* VERTEX INITIATES PHASE 3 STUDIES OF VX-445, TEZACAFTOR AND IVACAFTOR AS A TRIPLE COMBINATION REGIMEN FOR PEOPLE WITH CYSTIC FIBROSIS

* VERTEX PHARMACEUTICALS - FIRST PHASE 3 STUDY WILL EVALUATE ABOUT 360 PEOPLE WITH CF WHO HAVE 1 COPY OF F508DEL MUTATION & 1 MINIMAL FUNCTION MUTATION

* VERTEX PHARMACEUTICALS INC - SECOND PHASE 3 STUDY WILL EVALUATE APPROXIMATELY 100 PEOPLE WITH CF WHO HAVE TWO COPIES OF F508DEL MUTATION

* VERTEX - ANNOUNCES RESULTS FOR VX-561 WHEN DOSED AS PART OF A TRIPLE COMBO REGIMEN IN PHASE 2 STUDIES OF PEOPLE WITH 1 F508DEL MUTATION & 1 MINIMAL FUNCTION MUTATION

* VERTEX PHARMACEUTICALS INC - VX-561 WHEN DOESED AS PART OF THE TRIPLE COMBINATION REGIMENS WERE GENERALLY WELL TOLERATED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below